<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880811</url>
  </required_header>
  <id_info>
    <org_study_id>ESCC-AT</org_study_id>
    <nct_id>NCT04880811</nct_id>
  </id_info>
  <brief_title>Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification</brief_title>
  <official_title>Phase 2 Study of Afatinib Plus Toripalimab in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in&#xD;
      previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR&#xD;
      overexpression or EGFR amplification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measure of time from first response to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) or stable disease (SD) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>Until 30 days after the last treatment</time_frame>
    <description>Number of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measure of time from study treatment to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measure of time from study treatment to patient's death or lost to follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Afatinib plus toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib is orally administered at 40mg Qd of each 21 day cycle.</description>
    <arm_group_label>Afatinib plus toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.</description>
    <arm_group_label>Afatinib plus toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Having signed informed consent.&#xD;
&#xD;
          2. Age 18 to 70 years old.&#xD;
&#xD;
          3. Histologically confirmed esophageal squamous carcinoma&#xD;
&#xD;
          4. Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation&#xD;
             sequencing confirmed EGFR-amplification.&#xD;
&#xD;
          5. Computed tomography (CT) or magnetic resonance imaging (MRI) confirmed unresectable&#xD;
             metastasic or recurrent ESCC.&#xD;
&#xD;
          6. Refractory or intolerant to at least one regimen.&#xD;
&#xD;
          7. Measurable disease according to the Response Evaluation Criteria In Solid Tumors&#xD;
             (RECIST) 1.1 criteria(diameter of the lesion should be more than 10mm by spiral CT or&#xD;
             MRI, more than 20mm by common CT, the date of image should be less than 21 days before&#xD;
             enrollment)&#xD;
&#xD;
          8. Life expectancy of ≥3 month&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
         10. WBC&gt;3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet&gt;100,000/mm3,&#xD;
             Hb&gt;9g/dl，Bilirubin level &lt; 1.5 times ULN，Serum creatinine &lt;1.5 times ULN，ALT and&#xD;
             AST&lt;2.5 times ULN ，AKP &lt; 2.5 times ULN ，(≤5 times ULN in patients with liver&#xD;
             metastases)(within 7 days before enrollment)&#xD;
&#xD;
         11. No sever complication, such as active gastrointestinal bleeding, perforation,&#xD;
             jaundice, obstruction, non-cancerous fever&gt;38℃.&#xD;
&#xD;
         12. Good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently receiving other effective regimens.&#xD;
&#xD;
          2. Previous anticipate other clinical trial within 4 weeks before entering this study.&#xD;
&#xD;
          3. No measurable lesions, eg. pleural fluid and ascites.&#xD;
&#xD;
          4. With other malignancy within 5 year, except non-melanoma skin cancer and cervical&#xD;
             carcinoma in situ.&#xD;
&#xD;
          5. Heart failure or other sever organ dysfunction, eg. coronary artery disease,&#xD;
             myocardial infarction within the last 6 months.&#xD;
&#xD;
          6. Mentally abnormal or disable cognition,including central nervous system (CNS)&#xD;
             metastasis.&#xD;
&#xD;
          7. HIV infection, active hepatitis B or hepatitis C.&#xD;
&#xD;
          8. Unstable systemic diseases such as poorly controlled diabetes.&#xD;
&#xD;
          9. Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or&#xD;
             evidence of interstitial lung disease showed in X-ray/CT.&#xD;
&#xD;
         10. Keratitis, ulcerative keratitis or severe dry eye syndrome. Known hypersensitivity to&#xD;
             study drug.&#xD;
&#xD;
         11. Pregnancy or lactation period.&#xD;
&#xD;
         12. Active severe infection within 14 days&#xD;
&#xD;
         13. Contraindications of afatinib.&#xD;
&#xD;
         14. Pregnancy (determined by serum β-chorionic gonadotropin test) or breast-feeding&#xD;
&#xD;
         15. Gastrointestinal perforation and/or fistula occurred within 3 months before enrollment&#xD;
&#xD;
         16. Patients with active autoimmune disease or stable disease with high risk of recurrence&#xD;
&#xD;
         17. Use corticosteroids (dose of prednisone or similar drugs&gt; 10mg/day) or other&#xD;
             immunosuppressive agents within 14 days before enrollment&#xD;
&#xD;
         18. Live vaccine was injected within 4 weeks before enrollment&#xD;
&#xD;
         19. Previously received treatment with EFFR-TKI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhihao Lu, Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>13810549767@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital and Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>afatinib</keyword>
  <keyword>toripalimab</keyword>
  <keyword>EGFR Overexpression</keyword>
  <keyword>EGFR Amplification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

